艾弗迈克丁与妇科癌症:有哪些数据?
Vaidehi Mujumdar1, Marilyn Huang2, Lindsey Chippendale Smith3
1Atrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA.
Gynecologic oncology reports
|August 25, 2025
概括
对于寄生虫感染的Ivermectin,缺乏治疗妇科癌症的数据. 由于缺乏安全性和有效性的证据,研究人员警告不要在妇科癌症中使用它.
科学领域:
- 妇科瘤学
- 药理学
- 药物的转化
背景情况:
- 艾弗梅克丁是FDA批准的治疗寄生虫感染,如强硬菌病和菌病.
- 目前对ivermectin抗癌功能的研究主要局限于体外细胞系研究.
- 缺乏关于ivermectin作为妇科癌症治疗药物的全面数据.
研究的目的:
- 评估目前用于治疗妇科癌症的依据.
- 确定有关ivermectin在该患者群体中的安全性和有效性的知识差距.
- 提供关于ivermectin在妇科瘤学中的功效的临床建议.
主要方法:
- 现有临床研究和临床前数据的文献综述.
- 美国食品和药物管理局 (FDA) 批准的对ivermectin的说明进行分析.
- 评估专门用于妇科癌症的现有证据.
主要成果:
- 目前没有关于ivermectin对妇科癌症的疗效的数据.
- 对治疗癌症的ivermectin进行的临床研究仅限于细胞系观察.
- 在治疗妇科癌症方面,ivermectin的安全性和有效性尚未得到临床评估.
结论:
- 目前的临床证据不支持ivermectin用于治疗妇科癌症.
- 在治疗妇科癌症时,建议谨慎使用ivermectin.
- 需要进一步严格的临床试验,以确定ivermectin在妇科瘤学中的任何潜在作用.
相关概念视频
Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Infertility in Females
401
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
401
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K


